{"url":"https://newsforagent.com/news/2026-11-15/ambrosia-biosciences-obesityweek-oral-glp1-data","markdown_url":"https://newsforagent.com/news/2026-11-15/ambrosia-biosciences-obesityweek-oral-glp1-data.md","title":"Ambrosia Biosciences Posts Oral GLP-1 Data","headline":"Ambrosia Biosciences Presents Oral GLP-1 and GIP Data at ObesityWeek 2026","description":"Ambrosia Biosciences presented nonclinical data for oral GLP-1 agonist AMB-895, showing 8% mean weight loss in lean monkeys after 14 days of weekly dosing.","section":"Research & Clinical Trials","published_at":"2026-11-15T14:45:32+00:00","modified_at":"2026-11-15T14:45:32+00:00","author":"News Desk","key_takeaways":["Ambrosia Biosciences presented nonclinical data for AMB-895 and AMB-131 in poster sessions at ObesityWeek 2026.","AMB-895, an oral GLP-1 receptor agonist intended for once-weekly dosing, produced 8% mean weight loss from baseline at day 14 in lean non-human primates.","AMB-131, an oral GIP receptor antagonist, enhanced semaglutide-induced weight loss in a mouse model of diet-induced obesity.","Ambrosia closed a $100 million Series B financing in March 2026 to fund Phase 1 initiation of AMB-702."],"companies":[{"name":"Ambrosia Biosciences","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0000q7g/ambrosia-biosciences","website":"https://ambrosiabiosciences.com"}],"source":{"publisher":"PR Newswire","title":"Ambrosia Biosciences Announces the Nonclinical Data Profiles of Two Oral Small Molecule Programs: A GLP-1 Receptor Agonist Intended for Once-Weekly Dosing and a GIP Receptor Antagonist","url":"https://www.prnewswire.com/news-releases/ambrosia-biosciences-announces-the-nonclinical-data-profiles-of-two-oral-small-molecule-programs-a-glp-1-receptor-agonist-intended-for-once-weekly-dosing-and-a-gip-receptor-antagonist-302939600.html"},"other_sources":[{"publisher":"PR Newswire","url":"https://www.prnewswire.com/news-releases/obesity-week-2026--laekna-announces-poster-presentation-on-lae124-an-internally-discovered-oral-small-molecule-amylin-receptor-agonist-302937235.html"},{"publisher":"MarketScreener","url":"https://www.marketscreener.com/news/pfizer-secures-up-to-1-5-billion-from-blackstone-for-obesity-drug-development-ce785edbd18ef623"},{"publisher":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2026/11/11/3401043/0/en/glp-1-ras-incretin-based-therapies-competitive-landscape-analysis-key-developments-by-200-companies-shaping-the-treatment-landscape-delveinsight.html"}],"tags":["Research & Clinical Trials","Ambrosia Biosciences"],"body_markdown":"Ambrosia Biosciences presented nonclinical data on November 15, 2026 for two oral small molecule programs, including an 8% mean weight loss at day 14 in lean non-human primates for its once-weekly GLP-1 candidate. The company announced the poster presentations at ObesityWeek 2026, according to [PR Newswire](https://www.prnewswire.com/news-releases/ambrosia-biosciences-announces-the-nonclinical-data-profiles-of-two-oral-small-molecule-programs-a-glp-1-receptor-agonist-intended-for-once-weekly-dosing-and-a-gip-receptor-antagonist-302939600.html).\n\n## Inside the AMB-895 and AMB-131 Posters\n\n[Ambrosia Biosciences](https://akta.pro/company-profiles/0000q7g/ambrosia-biosciences) said AMB-895, a novel oral small molecule GLP-1 receptor agonist intended for once-weekly dosing, showed sustained target coverage greater than EC 70 over one week after a single 1 mg/kg oral dose in lean non-human primates. The candidate also produced sustained weight loss and reduced food intake over 14 days of once-weekly oral dosing in a lean non-human primate model. At 1 mg/kg, AMB-895 showed 8% mean weight loss from baseline at day 14.\n\nAMB-131, a novel oral small molecule GIP receptor antagonist, showed higher exposure and target coverage at 24 hours in both mouse and non-human primate models. The company said AMB-131 enhanced weight loss induced by semaglutide in a mouse model of diet-induced obesity.\n\n\"Many treatment options for people with diabetes and obesity are limited by route of administration, tolerability and scalability,\" said Nick Traggis, CEO. \"We also believe the future of metabolic disease treatment will include oral combination therapies that can be optimized to balance efficacy and tolerability, and we've designed our small molecule programs with that opportunity in mind.\"\n\n## Ambrosia's Funding and Earlier Data\n\nAmbrosia is a privately held drug discovery company based in Boulder that develops oral small molecule therapies for obesity and other metabolic disorders, according to akta.pro [company records](https://akta.pro/company-data). The same records show a $100 million oversubscribed Series B financing closed in March 2026, co-led by Blue Owl Healthcare Opportunities, Redmile Group and Deep Track Capital, to fund Phase 1 initiation of AMB-702 and other cardiometabolic programs. In June 2026, Ambrosia presented preclinical data for AMB-702 at the ADA 86th Scientific Sessions, reporting 12.6% placebo-adjusted mean weight loss after 7 days in lean non-human primates versus 5.4% for orforglipron at the same dose.\n\n## Other ObesityWeek 2026 Presentations\n\n[Laekna Therapeutics](https://www.prnewswire.com/news-releases/obesity-week-2026--laekna-announces-poster-presentation-on-lae124-an-internally-discovered-oral-small-molecule-amylin-receptor-agonist-302937235.html) announced on November 12, 2026 that LAE124, an oral small-molecule dual Amylin/Calcitonin receptor agonist for obesity, would be presented at ObesityWeek 2026 in Washington, D.C.; the drug is in IND-enabling studies. [MarketScreener](https://www.marketscreener.com/news/pfizer-secures-up-to-1-5-billion-from-blackstone-for-obesity-drug-development-ce785edbd18ef623) reported on November 11, 2026 that Pfizer said Blackstone will provide up to $1.5 billion through 2028 to fund its experimental monthly obesity treatment. [GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/11/3401043/0/en/glp-1-ras-incretin-based-therapies-competitive-landscape-analysis-key-developments-by-200-companies-shaping-the-treatment-landscape-delveinsight.html) carried a DelveInsight report on November 11, 2026 covering more than 200 pipeline drugs from over 180 companies, with approximately 30+ therapies in late-stage development.\n\n## What Comes Next for Ambrosia\n\nAmbrosia said its GLP-1 receptor agonist portfolio pairs AMB-895, designed for once-weekly dosing, with AMB-702, for once daily dosing, alongside its GIP receptor antagonist and amylin agonist programs. The company said the $100 million Series B is intended to fund Phase 1 initiation of AMB-702.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}